Volume 5, Issue 1 (2019)                   Pharm Biomed Res 2019, 5(1): 1-5 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghaffari J, Ghaffari N. Omalizumab for treatment of chronic urticaria: A review of effective dose. Pharm Biomed Res 2019; 5 (1) :1-5
URL: http://pbr.mazums.ac.ir/article-1-218-en.html
1- Pediatric Infectious Diseases Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2- Medical student, Mazandaran University of Medical Sciences, Sari, Iran
Abstract:   (1918 Views)
Omalizumab or Xolair®, a humanized anti-IgE monoclonal antibody, is effective and well-tolerated in patients with chronic spontaneous urticaria refractory to H1 antihistamines. The web search of several databases, including PubMed, EMBASE, Scopus, Google, SID, Magiran, and Irandoc, led to the selection of 60 articles. The search process was performed using the keywords of Xolair, omalizumab, urticaria, chronic urticaria, effect, and treatment. All studies have been conducted on people over 12 years of age with the exception of 2 articles investigating patients over 7 years old. Most studies have been performed on patients within the age range of 12-75 years and the maximum age of 81 years. Omalizumab has been administered at different doses for patients with chronic urticaria (75-600 mg). It has been shown to have a positive effect at all administered doses; however, it has the greatest effect when administered at the dose of 300 mg. The interval of subcutaneous injections was 2-6 weeks. In conclusion, the administration of this drug is effective at doses of 150 and 300 mg although the most effective dose is 300 mg.
Full-Text [PDF 785 kb]   (1886 Downloads)    
Type of Study: Review article | Subject: Clinical Pharmacy

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb